Vor Biopharma Inc. (VOR)

0.59

-0.04 (-6.94%)

At close: Apr 03, 2025, 3:59 PM

0.61

3.86%

After-hours: Apr 03, 2025, 05:08 PM EDT

Company Description

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.

It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.

The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers.

Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.

The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

Address: 100 Cambridgepark Drive Cambridge, Massachusetts United States
Website	https://www.vorbio.com

Name	Position
Dr. Robert Ang M.B.A., M.D., MBBS	President, Chief Executive Officer & Director
Dr. Han Choi M.D.	Chief Financial Officer
Tania Philipp	Chief People Officer
Amy Quinlan	Interim Principal Accounting Officer
David Phillips M.B.A.	Senior Vice President & Head of Quality
Dr. Eyal C. Attar M.D.	Chief Medical Officer
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.	Scientific Founder & Chairman of Scientific Advisory Board
Dr. Tirtha Chakraborty Ph.D.	Chief Scientific Officer & Head of Technical Operations
Samir Vattompadam M.S.	Senior Vice President of Portfolio Strategy & Program Management